CIPLA.NS or DVA: which has stronger momentum now?
As of 2026-09-01: CIPLA.NS LONG (90 bars, uPnL +7.7%, total return +3.1%) vs DVA LONG (142 bars, uPnL +32.8%, total return +23.4%). Momentum is the fourth gate — quality and valuation ceilings come first.
| Snapshot | 2026-09-01 · source: yahoo | |
|---|---|---|
| CIPLA.NS (Cipla) | DVA (DaVita) | |
| Market / sector | in · Pharma | us · Healthcare |
| Price | ₹1,407 | $178.88 |
| Quality score | —/100 | 100/100 |
| Engine signal | LONG · 90 bars · uPnL +7.7% | LONG · 142 bars · uPnL +32.8% |
| Total return | +3.1% | +23.4% |
Cite this page
Balance Labs Research Desk (2026-09-01). "CIPLA.NS or DVA: which has stronger momentum now?." balancelabs.app · https://balancelabs.app/stocks/compare/cipla.ns-vs-dva/q/cipla.ns-or-dva-stronger-momentum · CC BY 4.0
Ask anything
30 free credits monthly · no card required · research support, not advice
← CIPLA.NS vs DVA · snapshot 2026-09-01 · not investment advice